0.990
0.04 (4.21%)
| Previous Close | 0.950 |
| Open | 0.937 |
| Volume | 11,376 |
| Avg. Volume (3M) | 204,055 |
| Market Cap | 75,085,072 |
| Price / Sales | 9.42 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Operating Margin (TTM) | -571.68% |
| Diluted EPS (TTM) | -0.450 |
| Quarterly Revenue Growth (YOY) | 20.80% |
| Current Ratio (MRQ) | 4.49 |
| Operating Cash Flow (TTM) | -18.95 M |
| Levered Free Cash Flow (TTM) | -17.20 M |
| Return on Assets (TTM) | -48.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Clearside Biomedical, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 7.76% |
| % Held by Institutions | 20.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Carmignac Gestion | 31 Dec 2024 | 1,933,531 |
| Brown Wealth Management, Llc | 31 Dec 2024 | 100,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 6.00 (HC Wainwright & Co., 506.06%) | Buy |
| 6.00 (Chardan Capital, 506.06%) | Buy | |
| Median | 5.50 (455.56%) | |
| Low | 4.00 (Needham, 304.04%) | Buy |
| Average | 5.25 (430.30%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 0.960 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 31 Mar 2025 | 6.00 (506.06%) | Buy | 0.990 |
| 06 Mar 2025 | 6.00 (506.06%) | Buy | 0.976 | |
| Chardan Capital | 28 Mar 2025 | 6.00 (506.06%) | Buy | 0.950 |
| Citizens Capital Markets | 28 Mar 2025 | 5.00 (405.05%) | Buy | 0.950 |
| Needham | 28 Mar 2025 | 4.00 (304.04%) | Buy | 0.950 |
| 06 Mar 2025 | 6.00 (506.06%) | Buy | 0.976 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |